EDAP TMS SA closed an underwritten public offering of 8,425,000 American Depositary Shares at $4.75 per ADS on August 14, 2026. The company subsequently exercised its over-allotment option in full on the same date, adding 1,263,750 additional ADSs to the offering. This issuance is expected to close on August 19, 2026, and generate approximately $5.6 million in net proceeds for the company after deducting underwriting discounts and commissions. EDAP TMS SA operates in the medical technology industry, specializing in minimally invasive treatments for prostate cancer.
